Chris Holden

I'm Chris, and This is My Blog

Eric Lefkofsky Makes Progress Availing Medical Data To Medical Practitioners

by Chris Holden - April 5th, 2019.
Filed under: Cancer, Treatment.

Article Text:

Eric Lefkofsky, Tempus CEO, recently attended Precision Medicine World Conference giving a talk about “Transforming Big Data into Actionable Information”. He talked about his health-tech startup as well as the hurdles faced in the treatment of cancer and how data and precision medicine can be used to address the challenges. There has been a growing concern about absence of data for guided cancer treatments. Those are some of the problems that are facing the sector that needs to be addressed.

Eric Lefkofsky has built tech companies across various sectors which focused on messy data at scale, structuring unstructured, with more than 15000 people involved. In the wake of his wife suffering from cancer, Mr. Lefkofsky started conducting research on how to solve the broken cancer data infrastructure. That informed the idea for Tempus, a startup aiming at facilitating cancer treatment through Big Data analytics leveraging the recent human genome sequencing, science as well as technology advances.

Mr. Eric Lefkofsky has achieved a lot collaborating with top cancer centers in the country. They have managed to collect large amounts of clinical and molecular data. He now looks at saving the data captured from phase III clinical trials.

About three years down the line, Mr. Lefkofsky has managed to raise $130M in Series C round of financing and it was looking at closing additional $100M in funding. According to the accomplished entrepreneur, being on the limelight does not interest time. They are focused on solving problems and data challenges faced in cancer treatment. Tempus is working to avail rich data to pathologists, oncologists, surgeons, radiologists or researchers. They are looking at a time they will be saving between 100,000 to 600,000 people from dying annually.

Mr. Eric Lefkofsky and his company are focused in collecting phenotypic and drug-response data. The company’s team can abstract about 6,000 records per week leveraging natural language processing. The tech entrepreneur aims to decrease the time to about 15min/record. They aim at abstracting the records for about $10-15.

The first step they are taking toward ushering precision medicine as well as bringing the data to this problem is doing structuring clinical as well as molecular data at lower cost. Eric Lefkofsky and his team are dedicated to their course and time will tell what the future holds for the visionary people.

To Visit More Click Here

Leave a Reply

You must be logged in to post a comment.